

# Recombinant Human TNF- $\alpha$ /TNFA Protein (aa 57-233, His Tag)



Catalog Number:PKSH033165

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


## Description

<b>Synonyms</b>	Tumor Necrosis Factor; Cachectin; TNF-Alpha; Tumor Necrosis Factor Ligand Superfamily Member 2; TNF- $\alpha$ ; TNF; TNFA; TNFSF2
<b>Species</b>	Human
<b>Expression Host</b>	E.coli
<b>Sequence</b>	Gly57-Leu233
<b>Accession</b>	P01375
<b>Calculated Molecular Weight</b>	21.8 kDa
<b>Observed molecular weight</b>	18 kDa
<b>Tag</b>	N-His
<b>Bioactivity</b>	Measured in a cytotoxicity assay using L-929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. The ED <sub>50</sub> for this effect is 30-150 pg/ml.

## Properties

<b>Purity</b>	> 95 % as determined by reducing SDS-PAGE.
<b>Endotoxin</b>	< 1.0 EU per $\mu$ g of the protein as determined by the LAL method.
<b>Storage</b>	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
<b>Shipping</b>	This product is provided as lyophilized powder which is shipped with ice packs.
<b>Formulation</b>	Lyophilized from a 0.2 $\mu$ m filtered solution of 20mM PB, 100mM NaCl, pH 8.0. Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed man
<b>Reconstitution</b>	Please refer to the printed manual for detailed information.

## Data



> 95 % as determined by reducing SDS-PAGE.

## Background

Tumor Necrosis Factor- $\alpha$  (TNF- $\alpha$ ) is secreted by macrophages; monocytes; neutrophils; T-cells; and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF- $\alpha$  while cells that express CD8 secrete little or no TNF- $\alpha$ . Synthesis of TNF- $\alpha$  can be induced by many different stimuli including interferons; IL2; and GM-CSF. The clinical use of the potent anti-tumor activity of TNF- $\alpha$  has been limited by the proinflammatory side effects such as fever; dose-limiting hypotension; hepatotoxicity; intravascular thrombosis; and hemorrhage. Designing clinically applicable TNF- $\alpha$

## For Research Use Only

A Reliable Research Partner in Life Science and Medicine

Toll-free: 1-888-852-8623

Web: [www.elabscience.com](http://www.elabscience.com)

Tel: 1-832-243-6086

Email: [techsupport@elabscience.com](mailto:techsupport@elabscience.com)

Fax: 1-832-243-6017

# Recombinant Human TNF- $\alpha$ /TNFA Protein (aa 57-233, His Tag)



Catalog Number:PKSH033165

---

mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF- $\alpha$  that binds to murine TNF-R55 but not murine TNF-R7; exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF- $\alpha$ ; which binds to both murine TNF receptors. Based on these results; many TNF- $\alpha$  mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF- $\alpha$  High Active Mutant differs from the wild-type by amino acid substitution of amino acids 1-7 with Arg8; Lys9; Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.

---

## For Research Use Only

A Reliable Research Partner in Life Science and Medicine

Toll-free: 1-888-852-8623

Web: [www.elabscience.com](http://www.elabscience.com)

Tel: 1-832-243-6086

Email: [techsupport@elabscience.com](mailto:techsupport@elabscience.com)

Fax: 1-832-243-6017